Pharmaceutical company
Appears in 14 stories · Last updated Oct 27, 2026
Maker of durvalumab (Imfinzi), the control-arm drug beaten in HARMONi-GI1
Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on durvalumab (Imfinzi) plus chemo. That is a 25% lower risk of death in the Phase III HARMONi-GI1 trial, which Akeso presented at the ESMO 2026 Presidential Symposium in Madrid on October 25.
Updated Oct 27
Developer and marketer of IMFINZI (durvalumab)
Small cell lung cancer that has spread through the chest and beyond has held median survival near a year for decades. A phase 3 trial presented Oct. 24 at the ESMO Congress raised that to 21.1 months, about eight months longer than the comparison arm.
Updated Oct 26
Competitor with torvutatug samrotecan
Sofetabart mipitecan (Sofe-M) plus bevacizumab shrank tumors in 23 of 29 evaluable platinum-sensitive ovarian cancer patients, a 79.3% confirmed response rate. Every patient in the Phase 1 cohort had a response or stable disease, and the rate held in patients who had already taken a PARP inhibitor.
Co-developer and marketer of Enhertu outside Japan
The National Institute for Health and Care Excellence published final guidance on October 7, confirming that about 1,000 people a year in England can get Enhertu for HER2-low advanced breast cancer. The decision ended a 26-month dispute over price, after the UK raised what it will pay per quality-adjusted life year from £30,000 to £35,000.
Updated Oct 24
Holds FDA accelerated approval for Ultomiris in IgAN
The US Food and Drug Administration cleared AstraZeneca's Ultomiris on 21 October to reduce proteinuria, excess protein in the urine, in adults with primary immunoglobulin A nephropathy (IgAN). The approval is accelerated, so AstraZeneca must still show the drug preserves kidney function or risk losing the indication.
Updated Oct 23
Investor and clinical collaborator
AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.
Updated Oct 21
As of September 2026: Competitor via Zegfrovy, an oral EGFR inhibitor it licensed from Dizal
Patients with EGFR exon 20 insertion lung cancer have had almost no targeted options in the front-line setting. A phase 3 trial presented Sept. 13 in Seoul changed that. Adding the oral drug zipalertinib to chemotherapy delayed tumor progression by six months compared with chemotherapy alone.
Updated Sep 13
As of September 2026: Developer of tozorakimab
Millions of COPD patients who don't respond to current biologic treatments may soon have a new option. AstraZeneca's tozorakimab cut moderate-to-severe flare-ups by 29% to 34% in two late-stage trials, and unlike existing biologics, it worked across all blood eosinophil levels.
Updated Sep 10
As of September 2026: Markets Etcamah (camizestrant) after securing FDA accelerated approval
The Food and Drug Administration approved AstraZeneca's pill Etcamah (camizestrant) on September 4, 2026, for people with metastatic breast cancer whose tumors carry an estrogen receptor-1 (ESR1) mutation. It is the first cancer therapy approved based on a resistance mutation found in blood before scans show the disease has progressed.
Updated Sep 9
As of May 2026: Sponsor of camizestrant (NDA 220359) and Truqap (sNDA 218197/S-004)
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated May 31
As of May 2026: Maker of osimertinib (Tagrisso), the drug whose resistance the models replicate
Every year, hundreds of thousands of lung cancer patients start treatment with osimertinib, the leading targeted therapy for tumors driven by mutations in the EGFR gene. Most will respond, but nearly all will eventually stop responding as their cancers evolve resistance through a dozen different molecular escape routes. Until now, researchers had to work with messy lab models that made it hard to pin down which genetic change caused which failure.
As of May 2026: Manufacturer of acalabrutinib (Calquence); sponsor of the AMPLIFY trial
On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.
Updated May 29
As of May 2026: Developing AI-powered oncology drug development infrastructure
For decades, cancer drug trials have failed at a rate exceeding 95%, burning through $50–60 billion annually on treatments tested in patients unlikely to respond. On April 17, 2025, researchers from AstraZeneca and Tempus AI published in Cancer Cell results from the Predictive Biomarker Modeling Framework, a machine learning system using contrastive learning on existing clinical data. The system can identify which cancer patients will survive longer on immunotherapy versus chemotherapy. Applied retrospectively to completed phase 3 trials, it improved survival outcomes by 15% compared to traditional patient selection.
Updated May 27
As of May 2026: Co-commercializes Enhertu with Daiichi Sankyo; lead promoter in the U.S. market
The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.
Updated May 18
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
